Picture of Oncimmune Holdings logo

ONC Oncimmune Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

REG - Oncimmune Hldgs PLC - US$1.5m Contract Win with Top 10 Pharma Company

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240809:nRSI8093Za&default-theme=true

RNS Number : 8093Z  Oncimmune Holdings PLC  09 August 2024

 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

US$1.5m Contract Win with Top 10 Pharma Company

 

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine, is pleased to announce a significant new contract win with a Top 10 Global Pharma company.

 

 

Following a successful pilot carried out for a major pharmaceutical company,
Oncimmune has entered into an agreement for a major new project with the same
customer, with a contract value of at least US$1.5m.  This is one of the
largest contracts Oncimmune has entered into in its ImmunoINSIGHTS business
and demonstrates its ability to win significant repeat business from its key
customers.

 

During the pilot project, Oncimmune was able to demonstrate that it can
reliably profile Immunoglobulin E ("IgE") autoantibodies in blood serum using
its high-throughput bead-based platform, which Oncimmune believes to be a
technological breakthrough.  The new project is expected to be delivered over
the next six months, with the majority of the revenue therefore falling into
FY2025 and helping to underpin a sizeable portion of that year's forecasted
revenues.

 

The continued commercial traction, and expected acceleration due to the new
commercial team fully bedding in, give Oncimmune's Board confidence in its
revenue guidance for FY2024 of approximately £3m (2023: £1.15m from
continuing operations).  On the back of continued revenue growth, the Board
expects the Company to achieve profitability in FY2025.

 

With the business continuing to perform in line with its expectations,
Oncimmune has entered into discussions with IPF Management SA ("IPF") over
amending the terms of its existing credit facility, including the deferment of
capital repayments, to allow for additional investment in the Company's
operations.  Further details of the outcome of discussions will be provided
once concluded.

 

 

Martin Gouldstone, CEO of Oncimmune said:

 

"I am delighted that our world-leading scientific team has managed to
demonstrate our ability to measure IgE, which is much harder to detect in
blood serum than other immunoglobulins, using our high-throughput platform.
Not only did this enable us to win a major new contract with an existing
long-term Top 10 Pharma customer, it also opens a new technological offering,
in line with our strategic goals.

 

We are confident that, with this win and continued momentum of contracts, we
are in a strong position to meet our targets for FY24 and beyond, with
profitability expected in FY2025."

 

 

For further information:

 

Oncimmune Holdings plc

contact@oncimmune.com (mailto:contact@oncimmune.com)

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)

Nigel Birks, Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

 

Zeus (Joint Broker)

Dominic King, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

 

This Announcement contains inside information for the purposes of Article 7
of the Market Abuse Regulation No. 596/2014 as retained as part of UK law
by virtue of the European Union (Withdrawal) Act 2018 as
amended ("EUWA") and as it may be modified from time to time by or under
domestic law including, but not limited to, by the Market Abuse (Amendment)
(EU Exit) Regulations 2019/310). Upon the publication of this Announcement,
this inside information is now considered to be in the public domain.

 

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune
interactions through the autoantibody profile. Taking a platform approach to
generating insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations (CROs) to
discover novel biomarkers for the development of more targeted and effective
therapies across many immune-mediated diseases. Our mission at Oncimmune is to
enable precision medicine. We help our partners to discover novel biomarkers,
drug targets and predict treatment efficacy through the application of our
platform. We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of experience in the
field. Our aim is to make this an essential tool in drug discovery and
development.

 

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTBRGDICGGDGSI

Recent news on Oncimmune Holdings

See all news